Celine Pitou

982 total citations
24 papers, 641 citations indexed

About

Celine Pitou is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Celine Pitou has authored 24 papers receiving a total of 641 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Celine Pitou's work include Pancreatic and Hepatic Oncology Research (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Celine Pitou is often cited by papers focused on Pancreatic and Hepatic Oncology Research (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Celine Pitou collaborates with scholars based in United States, United Kingdom and Spain. Celine Pitou's co-authors include Iñaki F. Trocóniz, Jonathan M. Yingling, L. Buéno, Dinesh P. de Alwis, Sophie Glatt, Philip W. Iversen, Richard A. Walgren, Maria Garcia‐Cremades, Ruben A. Mesa and Srđan Verstovšek and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Celine Pitou

23 papers receiving 632 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Celine Pitou United States	14	347	289	116	113	82	24	641
Nicoletta Cordani Italy	14	311 0.9×	223 0.8×	65 0.6×	67 0.6×	68 0.8×	29	739
Erwan Pencreach France	17	323 0.9×	350 1.2×	82 0.7×	38 0.3×	58 0.7×	35	797
D. Gandara United States	11	478 1.4×	377 1.3×	85 0.7×	42 0.4×	59 0.7×	26	837
Michael Fluck Germany	11	379 1.1×	501 1.7×	223 1.9×	82 0.7×	26 0.3×	24	770
Jingrui Jiang United States	13	432 1.2×	251 0.9×	41 0.4×	170 1.5×	252 3.1×	22	868
Laure A Moutouh-de Parseval United States	6	922 2.7×	790 2.7×	128 1.1×	198 1.8×	165 2.0×	7	1.3k
Youwei Bi United States	14	225 0.6×	275 1.0×	55 0.5×	55 0.5×	19 0.2×	25	768
M. Thomas France	8	503 1.4×	758 2.6×	238 2.1×	64 0.6×	23 0.3×	20	1.1k
Nyam Kamsu-Kom France	10	662 1.9×	615 2.1×	101 0.9×	37 0.3×	23 0.3×	12	1.0k
Sönke Korfee Germany	4	359 1.0×	306 1.1×	28 0.2×	52 0.5×	72 0.9×	8	720

Countries citing papers authored by Celine Pitou

Since Specialization

Citations

This map shows the geographic impact of Celine Pitou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Celine Pitou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Celine Pitou more than expected).

Fields of papers citing papers by Celine Pitou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Celine Pitou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Celine Pitou. The network helps show where Celine Pitou may publish in the future.

Co-authorship network of co-authors of Celine Pitou

This figure shows the co-authorship network connecting the top 25 collaborators of Celine Pitou. A scholar is included among the top collaborators of Celine Pitou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Celine Pitou. Celine Pitou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Keller, Stuart, et al.. (2026). Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab. The Lancet Rheumatology.

Lassaletta, Álvaro, Lucas Moreno, Chitose Ogawa, et al.. (2023). Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).. Journal of Clinical Oncology. 41(16_suppl). 10039–10039. 1 indexed citations

Gallo, Gaia, et al.. (2022). Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. Advances in Therapy. 39(6). 2862–2872. 26 indexed citations

O’Hara, Mark H., Wells A. Messersmith, Hedy L. Kindler, et al.. (2020). Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. SHILAP Revista de lepidopterología. 6(1). 21–31. 37 indexed citations

Garcia‐Cremades, Maria, Celine Pitou, Philip W. Iversen, & Iñaki F. Trocóniz. (2019). Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies. The AAPS Journal. 21(2). 23–23. 8 indexed citations

Vergote, Ignace, Florian Heitz, Paul Buderath, et al.. (2019). A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer. Gynecologic Oncology. 156(1). 23–31. 43 indexed citations

Bendell, Johanna C., Helge Bischoff, Jimmy J. Hwang, et al.. (2019). A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. Investigational New Drugs. 38(4). 1145–1155. 20 indexed citations

Vergote, Ignace, Florian Heitz, Paul Buderath, et al.. (2019). A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer.. Journal of Clinical Oncology. 37(15_suppl). 5537–5537. 3 indexed citations

Palandri, Francesca, Maria R. Baer, Donald P. Quick, et al.. (2018). Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. Leukemia Research. 71. 82–88. 41 indexed citations

10.

Parra‐Guillén, Zinnia P., Víctor Mangas‐Sanjuán, Maria Garcia‐Cremades, et al.. (2018). Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts. Journal of Pharmacology and Experimental Therapeutics. 366(1). 96–104. 8 indexed citations

11.

Garcia‐Cremades, Maria, Celine Pitou, Philip W. Iversen, & Iñaki F. Trocóniz. (2018). Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer. European Journal of Pharmaceutical Sciences. 115. 296–303. 16 indexed citations

12.

Bendell, Johanna C., Valérie André, Alan L. Ho, et al.. (2018). Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma. Clinical Cancer Research. 24(9). 2082–2091. 59 indexed citations

13.

Verstovšek, Srđan, Ruben A. Mesa, Mohamed E. Salama, et al.. (2017). A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Leukemia Research. 61. 89–95. 31 indexed citations

14.

Goldman, Jonathan W., Lee S. Rosen, Anthony W. Tolcher, et al.. (2017). Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer. Investigational New Drugs. 36(4). 629–637. 13 indexed citations

15.

Garcia‐Cremades, Maria, Celine Pitou, Philip W. Iversen, & Iñaki F. Trocóniz. (2016). Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response Model. Journal of Pharmacology and Experimental Therapeutics. 360(3). 445–456. 9 indexed citations

16.

Schaefer, Eric, Martin Förster, D C Talbot, et al.. (2016). Phase 1b/2 trial of taladegib (LY2940680), a Hh/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer. European Journal of Cancer. 69. S131–S132. 4 indexed citations

17.

Kulanthaivel, P, et al.. (2015). Understanding Disease–Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window. Clinical Pharmacology & Therapeutics. 98(1). 76–86. 46 indexed citations

18.

Cohn, Allen Lee, Michael Lahn, Ann Cleverly, et al.. (2014). A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer. International Journal of Oncology. 45(6). 2221–2231. 37 indexed citations

19.

Verstovšek, Srđan, Ruben A. Mesa, Celine Pitou, et al.. (2011). Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET). Blood. 118(21). 2814–2814. 29 indexed citations

20.

Buéno, L., Dinesh P. de Alwis, Celine Pitou, et al.. (2007). Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice. European Journal of Cancer. 44(1). 142–150. 174 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact